Mesalamine is under clinical development by Dr. Falk Pharma and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mesalamine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mesalamine overview

Mesalazine (Salofalk, Canasa, Salo) is an aminosalicylate anti-inflammatory agent. It is formulated as suppositories, suspension, aerosol foam, enema for rectal route of administration, tablets, film coated tablets and granules for oral route of administration. It is indicated for the treatment of ulcerative colitis, eosinophilic esophagitis and ulcerative proctitis and crohn’s disease. It was under development for the treatment of diverticulitis, collagenous colitis and pediatric ulcerative colitis.

Dr. Falk Pharma overview

Dr. Falk Pharma is a pharmaceutical company that develops, manufactures, and supplies medicines for gastroenterology and hepatology. The company offers products for diseases such as inflammatory bowel, diverticular, constipation and irritable bowel, lipid metabolism disorder, and liver disease, among others. Dr. Falk Pharma also provides research that work in the areas of formulation, preclinical and clinical development. Dr. Falk Pharma provides doctors, pharmacists, and patients information related to diseases and therapies in gastroenterology and hepatology. The company has operations in Germany, Austria, Australia, Portugal, Great Britain, Ireland, Luxembourg, the Netherlands, Belgium, the UK, Spain, and Russia. Dr. Falk Pharma is headquartered in Freiburg, Baden-Wurttemberg, Germany.

For a complete picture of Mesalamine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.